PD-1Ab21-BCMA CAR-T consolidation for multiple myeloma with renal dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, interventional trial of autologous BCMA-directed CAR-T cells engineered to secrete a PD-1 antibody and IL-21 fusion protein given as consolidation after first-line therapy in patients with multiple myeloma and renal dysfunction. Eligible participants are over 14 years old, have received at least two courses of first-line treatment with at least a partial response, and must meet defined performance status and laboratory criteria. Treatment involves leukapheresis to collect patient T cells, ex vivo manufacture of the PD-1Ab21-BCMA CAR-T product, and infusion with inpatient monitoring for safety and efficacy endpoints. The study will track hematologic responses, renal function changes, and treatment-related toxicities at the Chinese PLA General Hospital in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age: Over 14 years old
2. Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR, and predicted survival of more than three months.
3. The hospital examination meets the following indicators:

   1. ECOG physical status score 0-2 or KPS score\>80 points
   2. Having sufficient venous access for single or intravenous blood collection, and no other blood cells Separation contraindications
   3. WBC≥1×109/L，LY≥0.3×109/L，
   4. ALT and AST ≤ 2.5 ULN
   5. Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L)
   6. PT:INR\<1.7 or PT prolonged by\<4s compared to normal value

Exclusion Criteria:

1. Pregnant or lactating women (the safety of this treatment for unborn babies is unknown, and the assessment of pregnancy status for female participants is negative in serum or urine pregnancy tests within 48 hours prior to infusion);
2. Any uncontrollable active infection;
3. Presence of active hepatitis B or C virus infection;
4. HIV/AIDS infection;
5. Has neurological disorders;
6. Within 2 weeks prior to signing the informed consent form, systemic use of steroid drugs (inhalable steroids may be used);
7. Allergies to immunotherapy and related drugs;
8. Currently, there are patients with heart disease or poorly controlled hypertension who require treatment;
9. Currently, patients with unstable or active ulcers or gastrointestinal bleeding;
10. Patients with a history of organ transplantation or waiting for organ transplantation;
11. Hyponatremia, blood sodium\<125mmol/L;
12. Baseline blood potassium\<3.5mmol/L (potassium can be supplemented before participating in the study to restore blood potassium levels above this level);
13. The patient needs anticoagulant therapy (such as warfarin or heparin);
14. The patient requires long-term antiplatelet therapy (aspirin, dose\>300mg/d); Clopidogrel, dose\>75mg/d).

Additionally,

1. Patients currently participating in other clinical trials;
2. Researchers believe that other reasons are not suitable for clinical trial participants.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Li-Ping Dou, Dr.
• Email: lipingruirui@163.com
• Phone: 86-010-66937232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCMA-TGFβ CAR-T Cells in Relapsed or Refractory Myeloma

  A one-arm phase 1 study tests a new BCMA-TGFβ CAR-T cell therapy to see if it is safe and provides signs of benefit in adults whose multiple myeloma has come back or persisted after prior treatments.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05976555

• CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma

  This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04300998

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Understanding CAR-T Toxicities After Cilta-Cel in Multiple Myeloma

  This observational study tests how patients with multiple myeloma respond to cilta-cel treatment by tracking toxicities and trying to spot biomarkers to guide care.

  Recruiting at 3 sites Icahn School of Medicine at Mount Sinai · San Francisco, California and 2 other locations · NCT07665307

• DC/MM fusion vaccine plus BCMA CAR-T for relapsed or refractory multiple myeloma

  This trial will test whether adding a personalized DC/MM fusion vaccine (with GM‑CSF) to standard BCMA CAR‑T therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07377435

• Voice monitoring for side effects during CAR T-cell therapy

  This project will test whether twice-daily smartphone voice recordings and brief daily neurologic checks can spot early neurologic side effects in adults receiving FDA-approved CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07249528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.